School of life Science, Shanghai University, 99 Shangda Road, 200444, China.
Guangxi Botanical Garden of Medicinal Plants, Nanning, Guangxi 530023, China.
Cytokine Growth Factor Rev. 2024 Oct;79:16-28. doi: 10.1016/j.cytogfr.2024.08.001. Epub 2024 Aug 10.
Tumor immunotherapy has garnered considerable attention, emerging as a new standard of care in cancer treatment. The conventional targets, such as VEGF and EGFR, have been extended to others including BRAF and PD-1/PD-L1, which have shown significant potential in recent cancer treatments. This review aims to succinctly overview the impact and mechanisms of therapies that modulate PD-1/PD-L1 expression by targeting VEGF, EGFR, LAG-3, CTLA-4 and BRAF. We investigated how modulation of PD-1/PD-L1 expression impacts growth factor signaling, shedding light on the interplay between immunomodulatory pathways and growth factor networks within the tumor microenvironment. By elucidating these interactions, we aim to provide insights into novel potential synergistic therapeutic strategies for cancer immunotherapy.
肿瘤免疫疗法备受关注，已成为癌症治疗的新标准。传统的靶点，如 VEGF 和 EGFR，已经扩展到包括 BRAF 和 PD-1/PD-L1 在内的其他靶点，这些靶点在最近的癌症治疗中显示出了巨大的潜力。本综述旨在简要概述通过靶向 VEGF、EGFR、LAG-3、CTLA-4 和 BRAF 来调节 PD-1/PD-L1 表达的治疗方法的影响和机制。我们研究了 PD-1/PD-L1 表达的调节如何影响生长因子信号，揭示了免疫调节途径与肿瘤微环境中的生长因子网络之间的相互作用。通过阐明这些相互作用，我们旨在为癌症免疫治疗的新的潜在协同治疗策略提供见解。
